There is no consensus regarding the duration of temozolomide (TMZ) treatment for glioblastoma
multiforme (GBM). We report a 53-year-old woman who had a left frontal GBM. The tumor
showed good response to TMZ treatment, which was discontinued after 5.5 years with
recurrence of tumor at the posterior fossa 6 months later, although there was no definite
tumor recurrence in the left frontal region. The tumor failed to respond to the reinstitution
of TMZ therapy. Continuous TMZ treatment may be necessary in GBM patients on prolonged
TMZ treatment despite improved neurological condition and imaging studies revealing
marked tumor regression.
Key-words:
Glioblastoma - temozolomide - tumor recurrence
